URL of this page: https://medlineplus.gov/druginfo/natural/923.html

Blue-green algae

What is it?

“Blue-green algae” describes a large and diverse group of simple, plant-like organisms found in salt water and some large fresh water lakes.

Blue-green algae products are used for many conditions, but so far, there isn’t enough scientific evidence to determine whether or not they are effective for any of them.

Blue-green algae are used as a source of dietary protein, B-vitamins, and iron. They are also used for weight loss, attention deficit-hyperactivity disorder (ADHD), hayfever, diabetes, stress, fatigue, anxiety, depression, and premenstrual syndrome (PMS) and other women’s health issues.

Some people use blue-green algae for treating precancerous growths inside the mouth, boosting the immune system, improving memory, increasing energy and metabolism, lowering cholesterol, preventing heart disease, healing wounds, and improving digestion and bowel health.

Blue-green algae are commonly found in tropical or subtropical waters that have a high-salt content, but some types grow in large fresh water lakes. The natural color of these algae can give bodies of water a dark-green appearance. The altitude, temperature, and sun exposure where the blue-green algae are grown dramatically influence the types and mix of blue-green algae in the water.

Some blue-green algae products are grown under controlled conditions. Others are grown in a natural setting, where they are more likely to be contaminated by bacteria, liver poisons (microcystins) produced by certain bacteria, and heavy metals. Choose only products that have been tested and found free of these contaminants.

You may have been told that blue-green algae are an excellent source of protein. But, in reality, blue-green algae is no better than meat or milk as a protein source and costs about 30 times as much per gram.

How effective is it?

Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, Ineffective, and Insufficient Evidence to Rate.

The effectiveness ratings for BLUE-GREEN ALGAE are as follows:

Insufficient evidence to rate effectiveness for...

  • Allergies. Early research shows that taking 2 grams of blue-green algae by mouth once daily for 6 months relieves allergy symptoms in adults.
  • Arsenic poisoning. Early research shows that taking a combination of blue-green algae and zinc by mouth twice daily for 12 weeks reduces arsenic levels and its effects on the skin in people living in areas with high arsenic levels in the drinking water.
  • Attention deficit-hyperactivity disorder (ADHD). Early research shows that taking a combination of blue-green algae, peony, ashwagandha, gotu kola, brahmi, and lemon balm improves ADHD.
  • Tics or twitching of the eyelids (blepharospasm or Meige syndrome). Beginning research shows that taking a specific blue-green algae product (Super Blue-Green Algae (SBGA), Cell Tech) by mouth for 6 months does not reduce eyelid spasms in people with blepharospasm.
  • Fatigue. Early research shows that taking 1 gram of blue-green algae by mouth 3 times daily does not improve fatigue in adults with chronic fatigue syndrome.
  • Diabetes. An early study shows that people with diabetes who take 1 gram of a blue-green algae product by mouth twice daily for 2 mouths have lower blood sugar levels.
  • Exercise performance. An early study shows that men are able to sprint for longer periods of time before becoming tired when they take 6 grams of blue-green algae by mouth daily for 4 weeks.
  • Hepatitis C. Research on the effects of blue-green algae in people with chronic hepatitis C has been inconsistent. In adults who were not yet treated or unresponsive to other treatments, taking 500 mg of spirulina blue-green algae by mouth 3 times daily for 6 months resulted in greater improvements in liver function compared to milk thistle. However, another study found that liver function worsened after one month of blue-green algae use.
  • High cholesterol. Early research shows that blue-green algae lowers cholesterol in people with normal or slightly elevated cholesterol levels; however, the research findings have been somewhat inconsistent. In one study, blue-green algae only lowered low-density lipoprotein (LDL or “bad”) cholesterol. In another study, glue-green algae lowered total cholesterol and LDL cholesterol, and increased high-density lipoprotein (HDL or “good”) cholesterol.
  • Malnutrition. Early research on the use of blue-green algae in combination with other dietary treatments for malnutrition in infants and children has been mixed. Weight gain was seen in undernourished children who were given spirulina blue-green algae with a combination of millet, soy and peanut for 8 weeks. However, in another study, children up to 3 years-old who were given 5 grams of blue-green algae daily for 3 months did not gain weight more than those given general treatments to improve nutrition alone.
  • Menopausal symptoms. An early study shows that taking 1.6 grams of a blue-green algae product by mouth daily for 8 weeks lowers anxiety and depression in women with menopause.
  • Precancerous mouth sores (oral leukoplakia). Early research findings show that taking 1 gram of spirulina blue-green algae (Spirulina fusiformis) daily by mouth for 12 months reduces oral leukoplakia in people who chew tobacco.
  • Weight loss. Research shows that taking spirulina blue-green algae does not seem to help reduce weight.
  • Premenstrual syndrome (PMS).
  • Immune system.
  • Anxiety.
  • Depression.
  • Memory.
  • Energy.
  • Heart disease.
  • Wound healing.
  • Digestion.
  • As a source of dietary protein, vitamin B12, and iron.
  • Other conditions.
More evidence is needed to rate the effectiveness of blue-green algae for these uses.

How does it work?

Blue-green algae have a high protein, iron, and other mineral content which is absorbed when taken orally. Blue-green algae are being researched for their potential effects on the immune system, swelling (inflammation), and viral infections.

Are there safety concerns?

Blue-green algae products that are free of contaminants, such as liver-damaging substances called microcystins, toxic metals, and harmful bacteria, are POSSIBLY SAFE for most people.

But blue-green algae products that are contaminated are LIKELY UNSAFE, especially for children. Children are more sensitive to contaminated blue-green algae products than adults.

Contaminated blue-green algae can cause liver damage, stomach pain, nausea, vomiting, weakness, thirst, rapid heartbeat, shock, and death. Don’t use any blue-green algae product that hasn’t been tested and found free of mycrocystins and other contamination.

Special precautions & warnings:

Pregnancy and breast-feeding: Not enough is known about the use of blue-green algae during pregnancy and breast-feeding. Stay on the safe side and avoid use.

“Auto-immune diseases” such as multiple sclerosis (MS), lupus (systemic lupus erythematosus, SLE), rheumatoid arthritis (RA), pemphigus vulgaris (a skin condition), and others: Blue-green algae might cause the immune system to become more active, and this could increase the symptoms of auto-immune diseases. If you have one of these conditions, it’s best to avoid using blue-green algae.

Phenylketonuria: The spirulina species of blue-green algae contains the chemical phenylalanine. This might make phenylketonuria worse. Avoid Spirulina species blue-green algae products if you have phenylketonuria.

Are there interactions with medications?

Be cautious with this combination.
Medications that decrease the immune system (Immunosuppressants)
Blue-green algae might increase the immune system. By increasing the immune system, blue-green algae might decrease the effectiveness of medications that decrease the immune system.

Some medications that decrease the immune system include azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3 (OKT3, Orthoclone OKT3), mycophenolate (CellCept), tacrolimus (FK506, Prograf), sirolimus (Rapamune), prednisone (Deltasone, Orasone), corticosteroids (glucocorticoids), and others.
Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs)
Blue-green algae might slow blood clotting. Taking blue-green algae along with medications that also slow clotting might increase the chances of bruising and bleeding.

Some medications that slow blood clotting include aspirin; clopidogrel (Plavix); nonsteroidal anti-inflammatory drugs (NSAIDs) such as diclofenac (Voltaren, Cataflam, others), ibuprofen (Advil, Motrin, others), and naproxen (Anaprox, Naprosyn, others); dalteparin (Fragmin); enoxaparin (Lovenox); heparin; warfarin (Coumadin); and others.

Are there interactions with herbs and supplements?

Herbs and supplements that might slow blood clotting
Blue-green algae might slow blood clotting. Taking blue-green algae along with herbs that also slow clotting might increase the chances of bruising and bleeding.

Some of these herbs include angelica, clove, danshen, garlic, ginger, ginkgo, Panax ginseng, red clover, turmeric, and others.

Are there interactions with foods?

There are no known interactions with foods.

What dose is used?

The appropriate dose of blue-green algae depends on several factors such as the user’s age, health, and several other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for blue-green algae. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult your pharmacist or physician or other healthcare professional before using.

Other names

AFA, Algae, Algas Verdiazul, Algues Bleu-Vert, Algues Bleu-Vert du Lac Klamath, Anabaena, Aphanizomenon flos-aquae, Arthrospira maxima, Arthrospira platensis, BGA, Blue Green Algae, Blue-Green Micro-Algae, Cyanobacteria, Cyanobactérie, Cyanophycée, Dihe, Espirulina, Hawaiian Spirulina, Klamath, Klamath Lake Algae, Lyngbya wollei, Microcystis aeruginosa, Microcystis wesenbergii, Nostoc ellipsosporum, Spirulina Blue-Green Algae, Spirulina Fusiformis, Spirulina maxima, Spirulina platensis, Spirulina pacifica, Spiruline, Spiruline d’Hawaii, Tecuitlatl.


To learn more about how this article was written, please see the Natural Medicines Comprehensive Database methodology.


  1. Habou H, Degbey H Hamadou B. Évaluation de l'efficacité de la supplémentation en spiruline du régime habituel des enfants atteints de malnutrition proteinoénergétique sévère (à propos de 56 cas). Thèse de doctorat en médecine Niger 2003;1.
  2. Bucaille P. Intérêt et efficacité de l'algue spiruline dans l'alimentation des enfants présentant une malnutrition protéinoénergétique en milieu tropical. Thèse de doctorat en médecine.Toulouse-3 université Paul-Sabatier 1990;Thèse de doctorat en médecine. Toulouse-3 université Paul-Sabatier:1.
  3. Sall MG, Dankoko B Badiane M Ehua E. Résultats d'un essai de réhabilitation nutritionnelle avec la spiruline à Dakar. Med Afr Noire 1999;46:143-146.
  4. Venkatasubramanian K, Edwin N in collaboration with Antenna technologies Geneva and Antenna trust Madurai. A study on preschool nutrition supplementation family income booster by Spirulina. Madurai Medical College 1999;20.
  5. Ishii, K., Katoch, T., Okuwaki, Y., and Hayashi, O. Influence of dietary Spirulina platensis on IgA level in human saliva. J Kagawa Nutr Univ 1999;30:27-33.
  6. Mishima T, Murata J, Toyoshima M, and et al. Inhibition of tumor invasion and metastasis by calcium spirulan (Ca-SP), a novel sulfated polysaccharide derived from a blue-green alga, Spirulina platensis. Clin Exp Metastasis 1998;16:541-550.
  7. Kato T, Takemoto K, Katayama H, and et al. Effects of spirulina (Spirulina platensis) on dietary hypercholesterolemia in rats. Nippon Eiyo Shokuryo Gakkaishi (J Jpn Soc Nutr Food Sci) 1984;37:323-332.
  8. Iwata K, Inayama T, and Kato T. Effects of spirulina platensis on fructose-induced hyperlipidemia in rats. Nippon Eiyo Shokuryo Gakkaishi (J Jpn Soc Nutr Food Sci) 1987;40:463-467.
  9. Becker EW, Jakober B, Luft D, and et al. Clinical and biochemical evaluations of the alga spirulina with regard to its application in the treatment of obesity. A double-blind cross-over study. Nutr Report Internat 1986;33:565-574.
  10. Mani UV, Desai S, and Iyer U. Studies on the long-term effect of spirulina supplementation on serum lipid profile and glycated proteins in NIDDM patients. J Nutraceut 2000;2:25-32.
  11. Johnson PE and Shubert LE. Accumulation of mercury and other elements by Spirulina (Cyanophyceae). Nutr Rep Int 1986;34:1063-1070.
  12. Gaese H. Chemical Composition and Potential Application of Spirulina platensis Biomass. International Journal of Agr.& Env. 2012;4.
  13. Mittalo A, Kumar A, and Rao T. Modulatory influence of Spirulina fusiformas on 7, 12-dimethylbenz[a]anthracene induced papillomagenesis in the skin of mice. Pharmaceut Biol 1998;36:341-346.
  14. Evets L. Means to normalize the levels of immunoglobulin E, using the food supplement spirulina. Russian Federation Committee of Patents and Trade 1994;Patent (RU ):2005486.
  15. Nakaya N, Homma Y, and Goto Y. Cholesterol lowering effect of spirulina. Nutrit Repor Internat 1988;37:1329-1337.
  16. Schwartz J, Shklar G, Reid S, and et al. Prevention of experimental oral cancer by extracts of Spirulina-Dunaliella algae. Nutr Cancer 1988;11:127-134.
  17. Parada, J. L., Zulpa, de Caire, Zaccaro de Mule, M. C., and Storni de Cano, M. M. Lactic acid bacteria growth promoters from Spirulina platensis. Int J Food Microbiol 12-22-1998;45:225-228. View abstract.
  18. Salazar, M., Martinez, E., Madrigal, E., Ruiz, L. E., and Chamorro, G. A. Subchronic toxicity study in mice fed Spirulina maxima. J Ethnopharmacol. 1998;62:235-241. View abstract.
  19. Ayehunie, S., Belay, A., Baba, T. W., and Ruprecht, R. M. Inhibition of HIV-1 replication by an aqueous extract of Spirulina platensis (Arthrospira platensis). J Acquir.Immune.Defic.Syndr.Hum Retrovirol. 5-1-1998;18:7-12. View abstract.
  20. Torres-Duran, P. V., Miranda-Zamora, R., Paredes-Carbajal, M. C., Mascher, D., Diaz-Zagoya, J. C., and Juarez-Oropeza, M. A. Spirulina maxima prevents induction of fatty liver by carbon tetrachloride in the rat. Biochem Mol.Biol Int 1998;44:787-793. View abstract.
  21. Yang, H. N., Lee, E. H., and Kim, H. M. Spirulina platensis inhibits anaphylactic reaction. Life Sci 1997;61:1237-1244. View abstract.
  22. Hayashi, K., Hayashi, T., and Kojima, I. A natural sulfated polysaccharide, calcium spirulan, isolated from Spirulina platensis: in vitro and ex vivo evaluation of anti-herpes simplex virus and anti-human immunodeficiency virus activities. AIDS res Hum Retroviruses 10-10-1996;12:1463-1471. View abstract.
  23. Salazar, M., Chamorro, G. A., Salazar, S., and Steele, C. E. Effect of Spirulina maxima consumption on reproduction and peri- and postnatal development in rats. Food Chem Toxicol 1996;34:353-359. View abstract.
  24. Gonzalez, de Rivera, Miranda-Zamora, R., Diaz-Zagoya, J. C., and Juarez-Oropeza, M. A. Preventive effect of Spirulina maxima on the fatty liver induced by a fructose-rich diet in the rat, a preliminary report. Life Sci 1993;53:57-61. View abstract.
  25. Sautier, C. and Tremolieres, J. [Food value of the spiruline algae to man]. Ann.Nutr.Aliment. 1975;29:517-534. View abstract.
  26. Narasimha, D. L., Venkataraman, G. S., Duggal, S. K., and Eggum, B. O. Nutritional quality of the blue-green alga Spirulina platensis Geitler. J Sci Food Agric 1982;33:456-460. View abstract.
  27. Chamorro, G. A., Herrera, G., Salazar, M., Salazar, S., and Ulloa, V. Short-term toxicity study of Spirulina in F3b generation rats. J Toxicol Clin Exp 1988;8:163-167. View abstract.
  28. Shklar, G. and Schwartz, J. Tumor necrosis factor in experimental cancer regression with alphatocopherol, beta-carotene, canthaxanthin and algae extract. Eur J Cancer Clin Oncol 1988;24:839-850. View abstract.
  29. Chamorro, G. A., Herrera, G., Salazar, M., Salazar, S., and Ulloa, V. Subchronic toxicity study in rats fed Spirulina. J Pharm Belg. 1988;43:29-36. View abstract.
  30. Oishi, S. and Watanabe, M. F. Acute toxicity of Microcystis aeruginosa and its cardiovascular effects. Environ Res 1986;40:518-524. View abstract.
  31. Torres-Duran, P. V., Ferreira-Hermosillo, A., Ramos-Jimenez, A., Hernandez-Torres, R. P., and Juarez-Oropeza, M. A. Effect of Spirulina maxima on postprandial lipemia in young runners: a preliminary report. J.Med.Food 2012;15:753-757. View abstract.
  32. Yu, B., Wang, J., Suter, P. M., Russell, R. M., Grusak, M. A., Wang, Y., Wang, Z., Yin, S., and Tang, G. Spirulina is an effective dietary source of zeaxanthin to humans. Br.J.Nutr. 2012;108:611-619. View abstract.
  33. Marcel, A. K., Ekali, L. G., Eugene, S., Arnold, O. E., Sandrine, E. D., von der, Weid D., Gbaguidi, E., Ngogang, J., and Mbanya, J. C. The effect of Spirulina platensis versus soybean on insulin resistance in HIV-infected patients: a randomized pilot study. Nutrients. 2011;3:712-724. View abstract.
  34. Ufelmann, H., Kruger, T., Luckas, B., and Schrenk, D. Human and rat hepatocyte toxicity and protein phosphatase 1 and 2A inhibitory activity of naturally occurring desmethyl-microcystins and nodularins. Toxicology 3-11-2012;293(1-3):59-67. View abstract.
  35. Giannuzzi, L., Sedan, D., Echenique, R., and Andrinolo, D. An acute case of intoxication with cyanobacteria and cyanotoxins in recreational water in Salto Grande Dam, Argentina. Mar.Drugs 2011;9:2164-2175. View abstract.
  36. Mitchell, G. V., Grundel, E., Jenkins, M., and Blakely, S. R. Effects of graded dietary levels of Spirulina maxima on vitamins A and E in male rats. J Nutr. 1990;120:1235-1240. View abstract.
  37. Berardesca, E., Bertona, M., Altabas, K., Altabas, V., and Emanuele, E. Reduced ultraviolet-induced DNA damage and apoptosis in human skin with topical application of a photolyase-containing DNA repair enzyme cream: clues to skin cancer prevention. Mol.Med.Rep. 2012;5:570-574. View abstract.
  38. Zeller, P., Clement, M., and Fessard, V. Similar uptake profiles of microcystin-LR and -RR in an in vitro human intestinal model. Toxicology 11-28-2011;290:7-13. View abstract.
  39. Moulis, G., Batz, A., Durrieu, G., Viard, C., Decramer, S., and Montastruc, J. L. Severe neonatal hypercalcemia related to maternal exposure to nutritional supplement containing Spirulina. Eur.J.Clin.Pharmacol. 2012;68:221-222. View abstract.
  40. Werner, K. A., Marquart, L., and Norton, S. A. Lyngbya dermatitis (toxic seaweed dermatitis). Int.J.Dermatol. 2012;51:59-62. View abstract.
  41. Konno, T., Umeda, Y., Umeda, M., Kawachi, I., Oyake, M., and Fujita, N. [A case of inflammatory myopathy with widely skin rash following use of supplements containing Spirulina]. Rinsho Shinkeigaku 2011;51:330-333. View abstract.
  42. Hofer, A., Legat, F. J., Gruber-Wackernagel, A., Quehenberger, F., and Wolf, P. Topical liposomal DNA-repair enzymes in polymorphic light eruption. Photochem.Photobiol.Sci. 2011;10:1118-1128. View abstract.
  43. Kaushal, S., Mathur, S. R., Mallick, S. R., and Ramam, M. Disseminated cutaneous, laryngeal, nasopharyngeal, and recurrent obstructive nasal rhinosporidiosis in an immunocompetent adult: a case report and review of literature. Int.J.Dermatol. 2011;50:340-342. View abstract.
  44. Chamorro, G. and Salazar, M. [Teratogenic study of Spirulina in mice]. Arch Latinoam.Nutr 1990;40:86-94. View abstract.
  45. Iwata, K., Inayama, T., and Kato, T. Effects of Spirulina platensis on plasma lipoprotein lipase activity in fructose-induced hyperlipidemic rats. J Nutr Sci Vitaminol.(Tokyo) 1990;36:165-171. View abstract.
  46. Nielsen, C. H., Balachandran, P., Christensen, O., Pugh, N. D., Tamta, H., Sufka, K. J., Wu, X., Walsted, A., Schjorring-Thyssen, M., Enevold, C., and Pasco, D. S. Enhancement of natural killer cell activity in healthy subjects by Immulina(R), a Spirulina extract enriched for Braun-type lipoproteins. Planta Med. 2010;76:1802-1808. View abstract.
  47. Mustafa, N., Periyasamy, P., and Kamaruddin, N. Steven Johnson syndrome in a patient with Cushing's disease. Med.J.Malaysia 2009;64:238-239. View abstract.
  48. Baroni, L., Scoglio, S., Benedetti, S., Bonetto, C., Pagliarani, S., Benedetti, Y., Rocchi, M., and Canestrari, F. Effect of a Klamath algae product ("AFA-B12") on blood levels of vitamin B12 and homocysteine in vegan subjects: a pilot study. Int.J.Vitam.Nutr.Res. 2009;79:117-123. View abstract.
  49. Ivanova, K. G., Stankova, K. G., Nikolov, V. N., Georgieva, R. T., Minkova, K. M., Gigova, L. G., Rupova, I. T., and Boteva, R. N. The biliprotein C-phycocyanin modulates the early radiation response: a pilot study. Mutat.Res. 2010;695(1-2):40-45. View abstract.
  50. Yamani, E., Kaba-Mebri, J., Mouala, C., Gresenguet, G., and Rey, J. L. [Use of spirulina supplement for nutritional management of HIV-infected patients: study in Bangui, Central African Republic]. Med.Trop.(Mars.) 2009;69:66-70. View abstract.
  51. Froscio, S. M., Fanok, S., and Humpage, A. R. Cytotoxicity screening for the cyanobacterial toxin cylindrospermopsin. J.Toxicol.Environ.Health A 2009;72:345-349. View abstract.
  52. Rasool, M. and Sabina, E. P. Appraisal of immunomodulatory potential of Spirulina fusiformis: an in vivo and in vitro study. J.Nat.Med. 2009;63:169-175. View abstract.
  53. Halidou, Doudou M., Degbey, H., Daouda, H., Leveque, A., Donnen, P., Hennart, P., and Dramaix-Wilmet, M. [The effect of spiruline during nutritional rehabilitation: systematic review]. Rev.Epidemiol.Sante Publique 2008;56:425-431. View abstract.
  54. Mazokopakis, E. E., Karefilakis, C. M., Tsartsalis, A. N., Milkas, A. N., and Ganotakis, E. S. Acute rhabdomyolysis caused by Spirulina (Arthrospira platensis). Phytomedicine. 2008;15(6-7):525-527. View abstract.
  55. Kraigher, O., Wohl, Y., Gat, A., and Brenner, S. A mixed immunoblistering disorder exhibiting features of bullous pemphigoid and pemphigus foliaceus associated with Spirulina algae intake. Int.J.Dermatol. 2008;47:61-63. View abstract.
  56. Shyam, R., Singh, S. N., Vats, P., Singh, V. K., Bajaj, R., Singh, S. B., and Banerjee, P. K. Wheat grass supplementation decreases oxidative stress in healthy subjects: a comparative study with spirulina. J Altern Complement Med 2007;13:789-791. View abstract.
  57. Chamorro-Cevallos, G., Garduno-Siciliano, L., Barron, B. L., Madrigal-Bujaidar, E., Cruz-Vega, D. E., and Pages, N. Chemoprotective effect of Spirulina (Arthrospira) against cyclophosphamide-induced mutagenicity in mice. Food Chem Toxicol 2008;46:567-574. View abstract.
  58. Hongsthong, A., Sirijuntarut, M., Prommeenate, P., Thammathorn, S., Bunnag, B., Cheevadhanarak, S., and Tanticharoen, M. Revealing differentially expressed proteins in two morphological forms of Spirulina platensis by proteomic analysis. Mol.Biotechnol. 2007;36:123-130. View abstract.
  59. Sharma, M. K., Sharma, A., Kumar, A., and Kumar, M. Spirulina fusiformis provides protection against mercuric chloride induced oxidative stress in Swiss albino mice. Food Chem Toxicol 2007;45:2412-2419. View abstract.
  60. Riss, J., Decorde, K., Sutra, T., Delage, M., Baccou, J. C., Jouy, N., Brune, J. P., Oreal, H., Cristol, J. P., and Rouanet, J. M. Phycobiliprotein C-phycocyanin from Spirulina platensis is powerfully responsible for reducing oxidative stress and NADPH oxidase expression induced by an atherogenic diet in hamsters. J Agric Food Chem 9-19-2007;55:7962-7967. View abstract.
  61. Guan, Y., Zhao, H. Y., Ding, X. F., and Zhu, Y. Y. [Analysis of the contents of elements in spirulina from different producing areas]. Guang.Pu.Xue.Yu Guang.Pu.Fen.Xi. 2007;27:1029-1031. View abstract.
  62. Trushina, E. N., Gladkikh, O., Gadzhieva, Z. M., Mustafina, O. K., and Pozdniakov, A. L. [The influence of Spirulina and Selen-Spirulina on some indexes of rat's immune status]. Vopr.Pitan. 2007;76:21-25. View abstract.
  63. Thaakur, S. R. and Jyothi, B. Effect of spirulina maxima on the haloperidol induced tardive dyskinesia and oxidative stress in rats. J Neural Transm. 2007;114:1217-1225. View abstract.
  64. Loke, M. F., Lui, S. Y., Ng, B. L., Gong, M., and Ho, B. Antiadhesive property of microalgal polysaccharide extract on the binding of Helicobacter pylori to gastric mucin. FEMS Immunol Med Microbiol. 2007;50:231-238. View abstract.
  65. Pandi, M., Shashirekha, V., and Swamy, M. Bioabsorption of chromium from retan chrome liquor by cyanobacteria. Microbiol.Res 5-11-2007; View abstract.
  66. Herrero, M., Vicente, M. J., Cifuentes, A., and Ibanez, E. Characterization by high-performance liquid chromatography/electrospray ionization quadrupole time-of-flight mass spectrometry of the lipid fraction of Spirulina platensis pressurized ethanol extract. Rapid Commun.Mass Spectrom. 2007;21:1729-1738. View abstract.
  67. Huang, Z. and Zheng, W. [Antagonistic effects of Se-rich Spirulina platensis on rat liver fibrosis]. Wei Sheng Yan.Jiu. 2007;36:34-36. View abstract.
  68. Rawn, D. F., Niedzwiadek, B., Lau, B. P., and Saker, M. Anatoxin-a and its metabolites in blue-green algae food supplements from Canada and Portugal. J Food Prot. 2007;70:776-779. View abstract.
  69. He, H. L., Chen, X. L., Wu, H., Sun, C. Y., Zhang, Y. Z., and Zhou, B. C. High throughput and rapid screening of marine protein hydrolysates enriched in peptides with angiotensin-I-converting enzyme inhibitory activity by capillary electrophoresis. Bioresour.Technol 2007;98:3499-3505. View abstract.
  70. Roy, K. R., Arunasree, K. M., Dhoot, A., Aparna, R., Reddy, G. V., Vali, S., and Reddanna, P. C-Phycocyanin inhibits 2-acetylaminofluorene-induced expression of MDR1 in mouse macrophage cells: ROS mediated pathway determined via combination of experimental and In silico analysis. Arch Biochem Biophys 3-15-2007;459:169-177. View abstract.
  71. Doshi, H., Ray, A., and Kothari, I. L. Biosorption of cadmium by live and dead Spirulina: IR spectroscopic, kinetics, and SEM studies. Curr Microbiol. 2007;54:213-218. View abstract.
  72. Roy, K. R., Arunasree, K. M., Reddy, N. P., Dheeraj, B., Reddy, G. V., and Reddanna, P. Alteration of mitochondrial membrane potential by Spirulina platensis C-phycocyanin induces apoptosis in the doxorubicinresistant human hepatocellular-carcinoma cell line HepG2. Biotechnol.Appl Biochem 2007;47(Pt 3):159-167. View abstract.
  73. Chamorro, G., Perez-Albiter, M., Serrano-Garcia, N., Mares-Samano, J. J., and Rojas, P. Spirulina maxima pretreatment partially protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Nutr Neurosci. 2006;9(5-6):207-212. View abstract.
  74. Sharma, M. K., Sharma, A., Kumar, A., and Kumar, M. Evaluation of protective efficacy of Spirulina fusiformis against mercury induced nephrotoxicity in Swiss albino mice. Food Chem Toxicol 2007;45:879-887. View abstract.
  75. Rasool, M., Sabina, E. P., and Lavanya, B. Anti-inflammatory effect of Spirulina fusiformis on adjuvant-induced arthritis in mice. Biol Pharm Bull. 2006;29:2483-2487. View abstract.
  76. Karkos, P. D., Leong, S. C., Arya, A. K., Papouliakos, S. M., Apostolidou, M. T., and Issing, W. J. 'Complementary ENT': a systematic review of commonly used supplements. J Laryngol.Otol. 2007;121:779-782. View abstract.
  77. Cheng, C. G., Hong, Q. H., Li, D. T., Fan, M. H., and Cai, X. D. [Determination of trace elements in Spirulina platensis (Notdst.) Geitl. by flame atomic absorption spectrometry combined with microsampling pulse nebulization technique]. Guang.Pu.Xue.Yu Guang.Pu.Fen.Xi. 2006;26:1735-1737. View abstract.
  78. Karaca, T. and Simsek, N. Effects of spirulina on the number of ovary mast cells in lead-induced toxicity in rats. Phytother Res 2007;21:44-46. View abstract.
  79. Balachandran, P., Pugh, N. D., Ma, G., and Pasco, D. S. Toll-like receptor 2-dependent activation of monocytes by Spirulina polysaccharide and its immune enhancing action in mice. Int Immunopharmacol. 12-5-2006;6:1808-1814. View abstract.
  80. Doshi, H., Ray, A., and Kothari, I. L. Bioremediation potential of live and dead Spirulina: spectroscopic, kinetics and SEM studies. Biotechnol.Bioeng. 4-15-2007;96:1051-1063. View abstract.
  81. Silveira, S. T., Burkert, J. F., Costa, J. A., Burkert, C. A., and Kalil, S. J. Optimization of phycocyanin extraction from Spirulina platensis using factorial design. Bioresour.Technol 2007;98:1629-1634. View abstract.
  82. Patel, A., Mishra, S., and Ghosh, P. K. Antioxidant potential of C-phycocyanin isolated from cyanobacterial species Lyngbya, Phormidium and Spirulina spp. Indian J Biochem Biophys 2006;43:25-31. View abstract.
  83. Madhyastha, H. K., Radha, K. S., Sugiki, M., Omura, S., and Maruyama, M. Purification of c-phycocyanin from Spirulina fusiformis and its effect on the induction of urokinase-type plasminogen activator from calf pulmonary endothelial cells. Phytomedicine 2006;13:564-569. View abstract.
  84. Khan, M., Shobha, J. C., Mohan, I. K., Rao Naidu, M. U., Prayag, A., and Kutala, V. K. Spirulina attenuates cyclosporine-induced nephrotoxicity in rats. J Appl Toxicol 2006;26:444-451. View abstract.
  85. Grzanna, R., Polotsky, A., Phan, P. V., Pugh, N., Pasco, D., and Frondoza, C. G. Immolina, a high-molecular-weight polysaccharide fraction of Spirulina, enhances chemokine expression in human monocytic THP-1 cells. J Altern Complement Med 2006;12:429-435. View abstract.
  86. Kuhad, A., Tirkey, N., Pilkhwal, S., and Chopra, K. Renoprotective effect of Spirulina fusiformis on cisplatin-induced oxidative stress and renal dysfunction in rats. Ren Fail. 2006;28:247-254. View abstract.
  87. Kuhad, A., Tirkey, N., Pilkhwal, S., and Chopra, K. Effect of Spirulina, a blue green algae, on gentamicin-induced oxidative stress and renal dysfunction in rats. Fundam.Clin Pharmacol 2006;20:121-128. View abstract.
  88. Mohan, I. K., Khan, M., Shobha, J. C., Naidu, M. U., Prayag, A., Kuppusamy, P., and Kutala, V. K. Protection against cisplatin-induced nephrotoxicity by Spirulina in rats. Cancer Chemother.Pharmacol 2006;58:802-808. View abstract.
  89. Ishimi, Y., Sugiyama, F., Ezaki, J., Fujioka, M., and Wu, J. Effects of spirulina, a blue-green alga, on bone metabolism in ovariectomized rats and hindlimb-unloaded mice. Biosci.Biotechnol.Biochem 2006;70:363-368. View abstract.
  90. Farooq, S. M., Ebrahim, A. S., Subramhanya, K. H., Sakthivel, R., Rajesh, N. G., and Varalakshmi, P. Oxalate mediated nephronal impairment and its inhibition by c-phycocyanin: a study on urolithic rats. Mol.Cell Biochem 2006;284(1-2):95-101. View abstract.
  91. Khan, M., Varadharaj, S., Shobha, J. C., Naidu, M. U., Parinandi, N. L., Kutala, V. K., and Kuppusamy, P. C-phycocyanin ameliorates doxorubicin-induced oxidative stress and apoptosis in adult rat cardiomyocytes. J Cardiovasc.Pharmacol 2006;47:9-20. View abstract.
  92. Han, L. K., Li, D. X., Xiang, L., Gong, X. J., Kondo, Y., Suzuki, I., and Okuda, H. [Isolation of pancreatic lipase activity-inhibitory component of spirulina platensis and it reduce postprandial triacylglycerolemia]. Yakugaku Zasshi 2006;126:43-49. View abstract.
  93. Murthy, K. N., Rajesha, J., Swamy, M. M., and Ravishankar, G. A. Comparative evaluation of hepatoprotective activity of carotenoids of microalgae. J Med Food 2005;8:523-528. View abstract.
  94. Khan, M., Varadharaj, S., Ganesan, L. P., Shobha, J. C., Naidu, M. U., Parinandi, N. L., Tridandapani, S., Kutala, V. K., and Kuppusamy, P. C-phycocyanin protects against ischemia-reperfusion injury of heart through involvement of p38 MAPK and ERK signaling. Am J Physiol Heart Circ.Physiol 2006;290:H2136-H2145. View abstract.
  95. Khan, M., Shobha, J. C., Mohan, I. K., Naidu, M. U., Sundaram, C., Singh, S., Kuppusamy, P., and Kutala, V. K. Protective effect of Spirulina against doxorubicin-induced cardiotoxicity. Phytother Res 2005;19:1030-1037. View abstract.
  96. Li, B., Gao, M. H., Zhang, X. C., and Chu, X. M. Molecular immune mechanism of C-phycocyanin from Spirulina platensis induces apoptosis in HeLa cells in vitro. Biotechnol.Appl Biochem 2006;43(Pt 3):155-164. View abstract.
  97. Premkumar, K., Abraham, S. K., Santhiya, S. T., and Ramesh, A. Protective effect of Spirulina fusiformis on chemical-induced genotoxicity in mice. Fitoterapia 2004;75:24-31. View abstract.
  98. Samuels, R., Mani, U. V., Iyer, U. M., and Nayak, U. S. Hypocholesterolemic effect of spirulina in patients with hyperlipidemic nephrotic syndrome. J Med Food 2002;5:91-96. View abstract.
  99. Gorban', E. M., Orynchak, M. A., Virstiuk, N. G., Kuprash, L. P., Panteleimonova, T. M., and Sharabura, L. B. [Clinical and experimental study of spirulina efficacy in chronic diffuse liver diseases]. Lik.Sprava. 2000;:89-93. View abstract.
  100. Gonzalez, R., Rodriguez, S., Romay, C., Gonzalez, A., Armesto, J., Remirez, D., and Merino, N. Anti-inflammatory activity of phycocyanin extract in acetic acid- induced colitis in rats. Pharmacol Res 1999;39:1055-1059. View abstract.
  101. Bogatov, N. V. [Selenium deficiency and its dietary correction in patients with irritable bowel syndrome and chronic catarrhal colitis]. Vopr.Pitan. 2007;76:35-39. View abstract.
  102. Yakoot, M. and Salem, A. Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. A pilot randomized, comparative clinical trial. BMC.Gastroenterol. 2012;12:32. View abstract.
  103. Micheletti, E., Colica, G., Viti, C., Tamagnini, P., and De, Philippis R. Selectivity in the heavy metal removal by exopolysaccharide-producing cyanobacteria. J.Appl.Microbiol. 2008;105:88-94. View abstract.
  104. Katz M, Levine AA, Kol-Degani H, Kav-Venaki L. A compound herbal preparation (CHP) in the treatment of children with ADHD: a randomized controlled trial. J Atten Disord 2010;14:281-91. View abstract.
  105. Chiu HF, Yang SP, Kuo YL, et al. Mechanisms involved in the antiplatelet effect of C-phycocyanin. Br J Nutr 2006;95:435-40. View abstract.
  106. Genazzani AD, Chierchia E, Lanzoni C, et al. [Effects of Klamath Algae extract on psychological disorders and depression in menopausal women: a pilot study]. Minerva Ginecol 2010;62:381-8. View abstract.
  107. Branger B, Cadudal JL, Delobel M, et al. [Spiruline as a food supplement in case of infant malnutrition in Burkina-Faso]. Arch Pediatr 2003;10:424-31. View abstract.
  108. Simpore J, Kabore F, Zongo F, et al. Nutrition rehabilitation of undernourished children utilizing Spiruline and Misola. Nutr J 2006;5:3. View abstract.
  109. Baicus C, Baicus A. Spirulina did not ameliorate idiopathic chronic fatigue in four N-of-1 randomized controlled trials.Phytother Res 2007;21:570-3. View abstract.
  110. Kalafati M, Jamurtas AZ, Nikolaidis MG, et al. Ergogenic and antioxidant effects of spirulina supplementation in humans. Med Sci Sports Exerc 2010;42:142-51. View abstract.
  111. Baicus C, Tanasescu C. Chronic viral hepatitis, the treatment with spiruline for one month has no effect on the aminotransferases. Rom J Intern Med 2002;40:89-94. View abstract.
  112. Yakoot M, Salem A. Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. A pilot randomized, comparative clinical trial. BMC,Gastroenterol 2012;12:32.
  113. Misbahuddin M, Islam A Z, Khandker S, et al. Efficacy of spirulina extract plus zinc in patients of chronic arsenic poisoning: a randomized placebo-controlled study. Clin Toxicol (Phila) 2006;44:135-41. View abstract.
  114. Cingi C, Conk-Dalay M, Cakli H, Bal C. The effects of spirulina on allergic rhinitis. Eur Arch Otorhinolaryngol 2008;265:1219-23. View abstract.
  115. Mani UV, Desai S, Iyer U. Studies on the long-term effect of spirulina supplementation on serum lipid profile and glycated proteins in NIDDM patients. J Nutraceut 2000;2:25-32.
  116. Nakaya N, Homma Y, Goto Y. Cholesterol lowering effect of spirulina. Nutr Rep Internat 1988;37:1329-37.
  117. Juarez-Oropeza MA, Mascher D, Torres-Duran PV, Farias JM, Paredes-Carbajal MC. Effects of dietary Spirulina on vascular reactivity.J.Med.Food 2009;12:15-20. View abstract.
  118. Park HJ, Lee YJ, Ryu HK, et al. A randomized double-blind, placebo-controlled study to establish the effects of spirulina in elderly Koreans. Ann.Nutr.Metab 2008;52:322-8. View abstract.
  119. Becker EW, Jakober B, Luft D, et al. Clinical and biochemical evaluations of the alga spirulina with regard to its application in the treatment of obesity. A double-blind cross-over study. Nutr Report Internat 1986;33:565-74.
  120. Mathew B, Sankaranarayanan R, Nair PP, et al. Evaluation of chemoprevention of oral cancer with Spirulina fusiforms. Nutr Cancer 1995;24:197-02. View abstract.
  121. Mao TK, Van de Water J, Gershwin ME. Effects of a Spirulina-based dietary supplement on cytokine production from allergic rhinitis patients. J Med Food 2005;8:27-30. View abstract.
  122. Lu HK, Hsieh CC, Hsu JJ, et al. Preventive effects of Spirulina platensis on skeletal muscle damage under exercise-induced oxidative stress. Eur J Appl Physiol 2006;98:220-6. View abstract.
  123. Hirahashi T, Matsumoto M, Hazeki K, et al. Activation of the human innate immune system by Spirulina: augmentation of interferon production and NK cytotoxicity by oral administration of hot water extract of Spirulina platensis. Int Immunopharmacol 2002;2:423-34. View abstract.
  124. Vitale S, Miller NR, Mejico LJ, et al. A randomized, placebo-controlled, crossover clinical trial of super blue-green algae in patients with essential blepharospasm or Meige syndrome. Am J Ophthalmol 2004;138:18-32. View abstract.
  125. Lee AN, Werth VP. Activation of autoimmunity following use of immunostimulatory herbal supplements. Arch Dermatol 2004;140:723-7. View abstract.
  126. Hayashi O, Katoh T, Okuwaki Y. Enhancement of antibody production in mice by dietary Spirulina platensis. J Nutr Sci Vitaminol (Tokyo) 1994;40:431-41.. View abstract.
  127. Dagnelie PC. Some algae are potentially adequate sources of vitamin B-12 for vegans. J Nutr 1997;2:379.
  128. Shastri D, Kumar M, Kumar A. Modulation of lead toxicity by Spirulina fusiformis. Phytother Res 1999;13:258-60.. View abstract.
  129. Romay C, Armesto J, Remirez D, et al. Antioxidant and anti-inflammatory properties of C-phycocyanin from blue-green algae. Inflamm Res 1998;47:36-41.. View abstract.
  130. Romay C, Ledon N, Gonzalez R. Further studies on anti-inflammatory activity of phycocyanin in some animal models of inflammation. Inflamm Res 1998;47:334-8.. View abstract.
  131. Dagnelie PC, van Staveren WA, van den Berg H. Vitamin B-12 from algae appears not to be bioavailable. Am J Clin Nutr 1991;53:695-7.. View abstract.
  132. Hayashi O, Hirahashi T, Katoh T, et al. Class specific influence of dietary Spirulina platensis on antibody production in mice. J Nutr Sci Vitaminol (Tokyo) 1998;44:841-51.. View abstract.
  133. Kushak RI, Drapeau C, Winter HS. The effect of blue-green algae Aphanizomenon flos-Aquae on nutrient assimilation in rats. JANA 2001;3:35-39.
  134. Kim HM, Lee EH, Cho HH, Moon YH. Inhibitory effect of mast cell-mediated immediate-type allergic reactions in rats by spirulina. Biochem Pharmacol 1998;55:1071-6. View abstract.
  135. Iwasa M, Yamamoto M, Tanaka Y, et al. Spirulina-associated hepatotoxicity. Am J Gastroenterol 2002;97:3212-13. View abstract.
  136. Gilroy DJ, Kauffman KW, Hall RA, et al. Assessing potential health risks from microcystin toxins in blue-green algae dietary supplements. Environ Health Perspect 2000;108:435-9. View abstract.
  137. Fetrow CW, Avila JR. Professional's Handbook of Complementary & Alternative Medicines. 1st ed. Springhouse, PA: Springhouse Corp., 1999.
  138. Anon. Health Canada announces results of blue-green algal products testing – only Spirulina found Microcystin-free. Health Canada, September 27, 1999; URL: www.hc-sc.gc.ca/english/archives/releases/99_114e.htm (Accessed 27 October 1999).
  139. Anon. Toxic algae in lake Sammamish. King County, WA. October 28, 1998; URL: splash.metrokc.gov/wlr/waterres/lakes/bloom.htm (Accessed 5 December 1999).
  140. Kushak RI, Drapeau C, Van Cott EM, Winter HH. Favorable effects of blue-green algae Aphanizomenon flos-aquae on rat plasma lipids. JANA 2000;2:59-65.
  141. Jensen GS, Ginsberg DJ, Huerta P, et al. Consumption of Aphanizomenon flos-aquae has rapid effects on the circulation and function of immune cells in humans. A novel approach to nutritional mobilization of the immune system. JANA 2000;2:50-6.
  142. Blue-Green Algae Protein Is a Promising Anti-HIV Microbicide Candidate. www.medscape.com/reuters/prof/2000/03/03.16/dd03160g.html (Accessed 16 March 2000).
  143. The Review of Natural Products by Facts and Comparisons. St. Louis, MO: Wolters Kluwer Co., 1999.
  144. Monographs on the medicinal uses of plant drugs. Exeter, UK: European Scientific Co-op Phytother, 1997.
Last reviewed - 02/14/2015